BR112021020509A2 - Glicoproteínas sialiladas - Google Patents

Glicoproteínas sialiladas

Info

Publication number
BR112021020509A2
BR112021020509A2 BR112021020509A BR112021020509A BR112021020509A2 BR 112021020509 A2 BR112021020509 A2 BR 112021020509A2 BR 112021020509 A BR112021020509 A BR 112021020509A BR 112021020509 A BR112021020509 A BR 112021020509A BR 112021020509 A2 BR112021020509 A2 BR 112021020509A2
Authority
BR
Brazil
Prior art keywords
shear stress
stable
sialylated glycoproteins
present
pharmaceutical
Prior art date
Application number
BR112021020509A
Other languages
English (en)
Other versions
BR112021020509A8 (pt
Inventor
D Patil Siddhesh
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112021020509A2 publication Critical patent/BR112021020509A2/pt
Publication of BR112021020509A8 publication Critical patent/BR112021020509A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

glicoproteínas sialiladas. a presente invenção refere-se a preparações farmacêuticas contendo imunoglobulinas hipersialiladas. as preparações são estáveis à tensão de cisalhamento. as composições farmacêuticas descritas na presente invenção fornecem composições de hsigg farmaceuticamente aceitáveis que são estáveis à tensão de cisalhamento (por exemplo, um número significativo de partículas subvisíveis não se forma quando a formulação é submetida à tensão de cisalhamento, como agitação, por exemplo, durante o transporte e, assim, pode ser transportada e manuseada na forma líquida.
BR112021020509A 2019-04-18 2020-04-17 Glicoproteínas sialiladas BR112021020509A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18
PCT/US2020/028863 WO2020215021A1 (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Publications (2)

Publication Number Publication Date
BR112021020509A2 true BR112021020509A2 (pt) 2022-03-15
BR112021020509A8 BR112021020509A8 (pt) 2023-01-10

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020509A BR112021020509A8 (pt) 2019-04-18 2020-04-17 Glicoproteínas sialiladas

Country Status (20)

Country Link
US (1) US20220211849A1 (pt)
EP (1) EP3955962A4 (pt)
JP (1) JP2022529168A (pt)
KR (1) KR20220002963A (pt)
CN (1) CN113795275A (pt)
AU (1) AU2020259492A1 (pt)
BR (1) BR112021020509A8 (pt)
CA (1) CA3137101A1 (pt)
CL (1) CL2021002668A1 (pt)
CO (1) CO2021013926A2 (pt)
CR (1) CR20210521A (pt)
EA (1) EA202192860A1 (pt)
EC (1) ECSP21078309A (pt)
IL (1) IL287306A (pt)
JO (1) JOP20210281A1 (pt)
MX (1) MX2021012710A (pt)
PE (1) PE20220383A1 (pt)
SG (1) SG11202110942SA (pt)
WO (1) WO2020215021A1 (pt)
ZA (1) ZA202109184B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
EP4248218A1 (en) 2020-11-20 2023-09-27 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE518886T1 (de) * 2003-06-09 2011-08-15 Redox Reactive Reagents L L C Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CA2615122A1 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
MY157239A (en) * 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
EP2900264A4 (en) * 2012-09-26 2016-05-25 Momenta Pharmaceuticals Inc GLYKOPROTEINZUBEREITUNGEN
EP3719122A1 (en) * 2013-05-02 2020-10-07 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
JP6594860B2 (ja) * 2013-05-29 2019-10-23 エフ．ホフマン−ラ ロシュ アーゲー シアル酸付加の定量的調節
WO2018131893A1 (ko) * 2017-01-11 2018-07-19 ㈜셀트리온 안정한 액체 제제

Also Published As

Publication number Publication date
CO2021013926A2 (es) 2021-10-29
SG11202110942SA (en) 2021-11-29
IL287306A (en) 2021-12-01
MX2021012710A (es) 2021-11-12
BR112021020509A8 (pt) 2023-01-10
KR20220002963A (ko) 2022-01-07
AU2020259492A1 (en) 2021-11-11
EP3955962A4 (en) 2022-12-14
EP3955962A1 (en) 2022-02-23
EA202192860A1 (ru) 2021-12-23
ZA202109184B (en) 2023-04-26
CA3137101A1 (en) 2020-10-22
US20220211849A1 (en) 2022-07-07
ECSP21078309A (es) 2021-11-30
CN113795275A (zh) 2021-12-14
CL2021002668A1 (es) 2022-05-27
JOP20210281A1 (ar) 2023-01-30
PE20220383A1 (es) 2022-03-18
WO2020215021A1 (en) 2020-10-22
JP2022529168A (ja) 2022-06-17
CR20210521A (es) 2022-04-01

Similar Documents

Publication Publication Date Title
BR112021020509A2 (pt) Glicoproteínas sialiladas
CO2020009997A2 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
CO7111300A2 (es) Formulación de anticuerpos
WO2016138030A3 (en) Compositions and methods for tolerizing the immune system to allergens
BR112021006598A2 (pt) composição farmacêutica líquida, e, kit
AR115283A1 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílicoe
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
MX2015014513A (es) Composicion que comprende sulfato de salbutamol.
BR112021006280A2 (pt) terapias imunoablativas
BR112019023260A2 (pt) Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos
BR112022007718A2 (pt) Composição farmacêutica, e, métodos de tratamento de um sujeito em necessidade e para produção de uma composição farmacêutica sólida
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
BR112015019580A2 (pt) processo para preparar uma solução aquosa, solução aquosa, medicamento, alimento, ingrediente de alimento ou suplemento alimentício e método para reduzir a assimilação calórica
BR112022000529A2 (pt) Composição farmacêutica
EA201890119A1 (ru) Смешанные составы
MX2022006130A (es) Composiciones inyectables de ácido ursodeoxicólico.
BR112017019831A2 (pt) uso de composições de astaxantina, composição, e, processo para preparação de alimento ou alimento animal
PH12020551798A1 (en) Improved pharmaceutical formulations
JOP20220045A1 (ar) تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها
BR112021026775A2 (pt) Processo para preparar uma composição que compreende um polipeptídeo de proteína d
Christofaro et al. Routes to insubordination: A typological perspective
CO2023003010A2 (es) Glicoproteínas sialiladas
PL421557A1 (pl) Preparat farmaceutyczny na bazie olejków eterycznych do leczenia infekcji grzybiczych jamy ustnej
CO2023016735A2 (es) Composición farmacéutica que contiene triterpenoides pentacíclicos
AR123578A1 (es) Mezclas de polisorbato que tienen distribución de ésteres de ácidos grasos modificados

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MOMENTA PHARMACEUTICALS, INC. (US)